Literature DB >> 9076898

Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro.

J B Hansen1, K R Huseby, N E Huseby, M Ezban, A Nordøy.   

Abstract

Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of the extrinsic coagulation system. In human plasma 70-85% is associated with apoB-containing lipoproteins whereas 10-20% exists in a carrier free form. The purpose of the present study was to assess the anticoagulant function of TFPI in complex with low density lipoproteins (LDL) on tissue factor (TF)-induced coagulation in vitro. LDL-TFPI complexes were isolated by preparative density gradient ultracentrifugation, LDL-free TFPI by preparative gel filtration and the anticoagulant properties were assessed by a diluted prothrombin time assay (dPT). LDL-free TFPI (0-0.46 U/ml) added to the dPT mixture, caused a prominent dose-dependent prolongation of dPT (0-42.2 sec.) which could be abolished by the addition of blocking anti-TFPI IgG. Contrary, increasing amounts of LDL-bound TFPI (0-4.0 U/ml) shortened dPT by 11.4 sec at the highest concentration. LDL-bound TFPI was not immunodetected by anti-TFPI IgG directed against the distal portion of the C-terminus, and appeared on Western blotting with a major band at 67 kDa and a weak band at 34 kDa which suggest that LDL-bound TFPI lack anticoagulant function due to carboxy terminal truncation. Our data provide evidence for the hypothesis that the anticoagulant function of TFPI is restricted to its carrier free form in human plasma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9076898     DOI: 10.1016/s0049-3848(97)00029-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  11 in total

1.  Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.

Authors:  Kenichi Ogiwara; Keiji Nogami; Tomoko Matsumoto; Midori Shima
Journal:  Int J Hematol       Date:  2014-04-01       Impact factor: 2.490

2.  Plasma tissue factor pathway inhibitor levels in patients with acute pancreatitis.

Authors:  Takeo Yasuda; Takashi Ueda; Keiko Kamei; Wataru Shinzaki; Hidehiro Sawa; Makoto Shinzeki; Yonson Ku; Yoshifumi Takeyama
Journal:  J Gastroenterol       Date:  2009-06-30       Impact factor: 7.527

3.  Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology.

Authors:  T J Girard; K Grunz; N M Lasky; J P Malone; G J Broze
Journal:  J Thromb Haemost       Date:  2018-10-22       Impact factor: 5.824

4.  Oxidized low-density lipoprotein impairs the anti-coagulant function of tissue-factor-pathway inhibitor through oxidative modification by its high association and accelerated degradation in cultured human endothelial cells.

Authors:  S Horie; S Hiraishi; Y Hirata; M Kazama; J Matsuda
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

5.  Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development.

Authors:  Shuchong Pan; Thomas A White; Tyra A Witt; Anca Chiriac; Cheri S Mueske; Robert D Simari
Journal:  Circ Res       Date:  2009-08-27       Impact factor: 17.367

6.  Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.

Authors:  Tilman M Hackeng; Kristin M Seré; Guido Tans; Jan Rosing
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-17       Impact factor: 11.205

7.  Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and Protein S in people with haemophilia.

Authors:  Paul E R Ellery; Ida Hilden; Peter Thyregod; Nicholas D Martinez; Susan A Maroney; Joan C Gill; Alan E Mast
Journal:  Haemophilia       Date:  2019-10-14       Impact factor: 4.287

Review 8.  Tissue factor pathway inhibitor as a multifunctional mediator of vascular structure.

Authors:  Eric W Holroyd; Thomas A White; Shuchong Pan; Robert D Simari
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

9.  Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S.

Authors:  Paul E R Ellery; Ida Hilden; Ken Sejling; Mette Loftager; Nicholas D Martinez; Susan A Maroney; Alan E Mast
Journal:  Res Pract Thromb Haemost       Date:  2017-12-29

10.  Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.

Authors:  Salvatore Santamaria; Natalia Reglińska-Matveyev; Magdalena Gierula; Rodney M Camire; James T B Crawley; David A Lane; Josefin Ahnström
Journal:  J Biol Chem       Date:  2017-04-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.